Tagged: egenesis

Jennifer Bergheiser is the Chief Business Officer of eGenesis, the Cambridge biotech turning gene-edited pig organs into a real answer to the transplant waitlist. She runs corporate strategy and all portfolio and commercial development, drawing on more than two decades across big pharma, venture capital, and consulting. Her resume runs from screening deals at Domain Associates to steering the blockbuster autoimmune drug Stelara at Centocor/Johnson & Johnson. At eGenesis she helps commercialize one of medicine's boldest bets: organs grown in pigs, edited dozens of times over, transplanted into living humans.